Abstract Streptococcus pyogenes (Group A Streptococcus; GAS) is exquisitely adapted to
the human host, resulting in asymptomatic infection, pharyngitis, pyoderma, scarlet fever or …

The production and use of antibiotics are becoming increasingly common worldwide, and
the problem of antibiotic resistance is increasing alarmingly. Drug‐resistant infections …

A new variant of Streptococcus pyogenes serotype M1 (designated 'M1UK') has been
reported in the United Kingdom, linked with seasonal scarlet fever surges, marked increase …

Recent advances in ultra-high-throughput sequencing technology and metagenomics have
led to a paradigm shift in microbial genomics from few genome comparisons to large-scale …

Mobile genetic elements (MGEs), such as plasmids and integrative and conjugative
elements (ICEs), are main drivers for the spread of antibiotic resistance (AR). Coevolution …

Summary Background Since 2014, England has seen increased scarlet fever activity
unprecedented in modern times. In 2016, England's scarlet fever seasonal rise coincided …

Abstract Group A Streptococcus (GAS; Streptococcus pyogenes) is a bacterial pathogen for
which a commercial vaccine for humans is not available. Employing the advantages of high …

Estimating the rates at which bacterial genomes evolve is critical to understanding major
evolutionary and ecological processes such as disease emergence, long-term host …

Background After decades of decreasing scarlet fever incidence, a dramatic increase was
seen in England beginning in 2014. Investigations were launched to assess clinical and …

Group A Streptococcus (GAS; Streptococcus pyogenes) is a nearly ubiquitous human
pathogen responsible for a significant global disease burden. No vaccine exists, so …